Latest news with #GenerallyAcceptedAccountingPrinciples
Yahoo
5 days ago
- Business
- Yahoo
Analyst flags new quantum computing stocks to buy
Analyst flags new quantum computing stocks to buy originally appeared on TheStreet. Last week, investors took note as a group of unexpected tech stocks started rising steadily. These companies weren't part of the Magnificent 7, a group of tech leaders responsible for most of the sector's growth. In fact, they often fly under most investors' radar. The companies were part of the quantum computing field. This fast-growing market centers around a type of computing that leverages the principles of quantum mechanics, solving complex problems by utilizing quantum bits (qubits) of information at significantly higher speeds than traditional computers. 💵💰💰💵 While quantum computing is sometimes overshadowed by artificial intelligence (AI), the industry has been making strides lately, particularly by one company. Its most recent news sent quantum computing stocks surging last week, though the momentum has since cooled. However, one financial expert believes the sector is poised for growth. He recently flagged a few quantum computing stocks as likely winners. When quantum computing stocks are trending, it's often due to updates from D-Wave Quantum () . A leader in practical quantum computing, D-Wave has emerged as the industry's leader, rising more than 470% over the past two Street veteran Stephen Guilfoyle, who follows the sector closely, recently highlighted the progress demonstrated both by D-Wave and its peer Quantum Computing () , a company that produces photonic hardware solutions for quantum machines. While Guilfoyle admits that he prematurely exited his position in D-Wave, he now sees it as a small-cap stock that is 'ripe for the picking' for investors looking to gain exposure to the fast-growing quantum computing industry. While he describes QBTS as being 'more ripe' than QUBT, he sees potential in both stocks. Earlier this month, D-Wave reported extremely strong Q1 earnings, setting records for both Generally Accepted Accounting Principles (GAAP) gross profit and quarterly end cash position. Guilfoyle highlighted both companies' earnings progress in a recent analysis, stating: 'Two weeks ago, Quantum Computing went to the tape with the firm's first quarter financial results. The firm posted a GAAP EPS of $0.11, which was a surprise profit, on revenue of just $39,000. That top-line number, believe it or not, was good enough for year-over-year growth of 44%. D-Wave, on the other hand, in early May, posted a Q1 GAAP EPS of -$0.02 on revenue of $15 million. That number, while still minuscule in our world, was enough to drive year-over-year growth of 507%.' More Wall Street News: Billionaire fund manager dumps Tesla in favor of other tech stock Top analyst sends bold message on S&P 500 Billionaire fund manager, skeptical of AI, backs shocking stock The analyst also flags a positive change for D-Wave, stating that its balance sheet had improved and should no longer be considered inferior to Quantum Computing's. While he adds that D-Wave's books include a few longer-term liabilities, he notes that it has adequate cash to address them should the need arise. In his analysis, Guilfoyle is careful to note that by traditional financial standards, both QBTS and QUBT should be considered 'grossly overvalued.' He notes, though, that capital is still flowing into Palantir Technologies, an AI-focused software producer that is also considered overvalued and is currently up almost 500% for the TheStreet reported earlier this year, several quantum computing stocks surged late in 2024, leading to speculation that their high valuations could pose problems in the near future. While these companies may be overvalued, Guilfoyle doesn't seem worried about the future of the industry. He still believes that quantum computing is a sector ripe with potential, comparing it to another area of technology that has boomed recently. 'Generative AI is the latest and greatest thing now in the technology world and will likely be with us from anywhere from a long time to something close to the rest of conceivable time as it evolves,' he states. 'That said, quantum computing will be far more powerful and speedy than any supercomputer invented so far. Quantum computing, in my amateur opinion, remains the next great thing.' If he is correct, companies like D-Wave and Quantum Computing are likely well-positioned to help lead the charge as this new frontier of technology continues to mint a new generation of market flags new quantum computing stocks to buy first appeared on TheStreet on May 28, 2025 This story was originally reported by TheStreet on May 28, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Star
6 days ago
- Business
- The Star
Nvidia announces financial results for Q1 of fiscal 2026
SAN FRANCISCO, May 28 (Xinhua) -- Nvidia on Wednesday reported revenue of 44.1 billion U.S. dollars for the first quarter of fiscal 2026 ended April 27, 2025, up 12 percent from the previous quarter and up 69 percent from a year ago. Its quarterly Generally Accepted Accounting Principles (GAAP) net income was 18.8 billion dollars, down 15 percent from the previous quarter and up 26 percent from a year ago. The quarterly revenue of Nvidia's Data Center was 39.1 billion dollars, up 10 percent from the previous quarter and up 73 percent from a year ago. Its first-quarter Gaming revenue was a record 3.8 billion dollars, up 48 percent from the previous quarter and up 42 percent from a year ago. The first-quarter revenue of Professional Visualization was 509 million dollars, flat with the previous quarter and up 19 percent from a year ago. The Automotive revenue for the quarter was 567 million dollars, down 1 percent from the previous quarter and up 72 percent from a year ago. On April 9, 2025, Nvidia was informed by the U.S. government that a license is required for exports of its H20 products into the China market. As a result of these new requirements, Nvidia incurred a 4.5 billion dollar charge in the first quarter of fiscal 2026 associated with H20 excess inventory and purchase obligations as the demand for H20 diminished, the company said. Sales of H20 products were 4.6 billion dollars for the first quarter of fiscal 2026 prior to the new export licensing requirements. Nvidia was unable to ship an additional 2.5 billion dollars of H20 revenue in the first quarter, according to the company. For the quarter, GAAP and non-GAAP gross margins were 60.5 percent and 61.0 percent, respectively. Excluding the 4.5 billion dollar charge, first quarter non-GAAP gross margin would have been 71.3 percent. For the quarter, GAAP and non-GAAP earnings per diluted share were 0.76 dollars and 0.81 dollars, respectively. Excluding the 4.5 billion dollar charge and related tax impact, first quarter non-GAAP diluted earnings per share would have been 0.96 dollars, Nvidia said in its financial report. "Our breakthrough Blackwell NVL72 AI supercomputer is now in full-scale production across system makers and cloud service providers," said Jensen Huang, founder and CEO of Nvidia. "Global demand for NVIDIA's AI infrastructure is incredibly strong. AI inference token generation has surged tenfold in just one year, and as AI agents become mainstream, the demand for AI computing will accelerate. Countries around the world are recognizing AI as essential infrastructure - just like electricity and the internet - and Nvidia stands at the center of this profound transformation," he noted. "We specialize in markets where our computing platforms can provide tremendous acceleration for applications. These platforms incorporate processors, interconnects, software, algorithms, systems. Our platforms address four large markets: Data Center, Gaming, Professional Visualization, and Automotive," said Colette Kress, Nvidia's executive vice president and chief financial officer. The company confirmed that it is building factories in the United States and working with its partners to produce Nvidia AI supercomputers in the country. Nvidia's outlook for revenue in the second quarter of fiscal 2026 is 45.0 billion dollars, plus or minus 2 percent. This outlook reflects a loss in H20 revenue of approximately 8.0 billion dollars due to the recent export control limitations. GAAP and non-GAAP gross margins in the second quarter are expected to be 71.8 percent and 72.0 percent, respectively, plus or minus 50 basis points. Nvidia will pay its next quarterly cash dividend of 0.01 dollars per share on July 3, 2025, to all shareholders of record on June 11, 2025.
Miami Herald
6 days ago
- Business
- Miami Herald
Analyst flags new quantum computing stocks to buy
Last week, investors took note as a group of unexpected tech stocks started rising steadily. These companies weren't part of the Magnificent 7, a group of tech leaders responsible for most of the sector's growth. In fact, they often fly under most investors' radar. The companies were part of the quantum computing field. This fast-growing market centers around a type of computing that leverages the principles of quantum mechanics, solving complex problems by utilizing quantum bits (qubits) of information at significantly higher speeds than traditional computers. Don't miss the move: Subscribe to TheStreet's free daily newsletter While quantum computing is sometimes overshadowed by artificial intelligence (AI), the industry has been making strides lately, particularly by one company. Its most recent news sent quantum computing stocks surging last week, though the momentum has since cooled. However, one financial expert believes the sector is poised for growth. He recently flagged a few quantum computing stocks as likely winners. When quantum computing stocks are trending, it's often due to updates from D-Wave Quantum (QBTS) . A leader in practical quantum computing, D-Wave has emerged as the industry's leader, rising more than 470% over the past two quarters. Related: Quantum computing stock surges after surprising announcement Wall Street veteran Stephen Guilfoyle, who follows the sector closely, recently highlighted the progress demonstrated both by D-Wave and its peer Quantum Computing (QUBT) , a company that produces photonic hardware solutions for quantum machines. While Guilfoyle admits that he prematurely exited his position in D-Wave, he now sees it as a small-cap stock that is "ripe for the picking" for investors looking to gain exposure to the fast-growing quantum computing industry. While he describes QBTS as being "more ripe" than QUBT, he sees potential in both stocks. Earlier this month, D-Wave reported extremely strong Q1 earnings, setting records for both Generally Accepted Accounting Principles (GAAP) gross profit and quarterly end cash position. Guilfoyle highlighted both companies' earnings progress in a recent analysis, stating: More Wall Street News: Billionaire fund manager dumps Tesla in favor of other tech stockTop analyst sends bold message on S&P 500Billionaire fund manager, skeptical of AI, backs shocking stock The analyst also flags a positive change for D-Wave, stating that its balance sheet had improved and should no longer be considered inferior to Quantum Computing's. While he adds that D-Wave's books include a few longer-term liabilities, he notes that it has adequate cash to address them should the need arise. In his analysis, Guilfoyle is careful to note that by traditional financial standards, both QBTS and QUBT should be considered "grossly overvalued." He notes, though, that capital is still flowing into Palantir Technologies, an AI-focused software producer that is also considered overvalued and is currently up almost 500% for the year. Related: IonQ CEO's strong 4-word message sends stock soaring As TheStreet reported earlier this year, several quantum computing stocks surged late in 2024, leading to speculation that their high valuations could pose problems in the near future. While these companies may be overvalued, Guilfoyle doesn't seem worried about the future of the industry. He still believes that quantum computing is a sector ripe with potential, comparing it to another area of technology that has boomed recently. If he is correct, companies like D-Wave and Quantum Computing are likely well-positioned to help lead the charge as this new frontier of technology continues to mint a new generation of market winners. Related: Veteran fund manager unveils eye-popping S&P 500 forecast The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Associated Press
27-05-2025
- Business
- Associated Press
Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics
Transaction will augment Lilly's efforts to advance non-opioid medicines for pain management INDIANAPOLIS, May 27, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics, Inc. ('SiteOne'), a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, today announced a definitive agreement for Lilly to acquire SiteOne. The transaction includes STC-004, a Phase 2 ready Nav1.8 inhibitor being studied for the treatment of pain. STC-004 may represent a next-generation, non-opioid treatment for patients suffering from chronic pain. 'The global burden of chronic pain continues to increase, and an effective non-opioid treatment remains elusive,' said Mark Mintun, Lilly group vice president Neuroscience Research and Development. 'Lilly is eager to continue the development of STC-004 with the outstanding SiteOne team as part of our efforts to advance novel, addiction-free pain therapies. Innovation in pain management is critical to address the unmet needs of millions of patients around the world.' Under the terms of the agreement, Lilly will acquire SiteOne and SiteOne shareholders could receive up to $1.0 billion in cash, inclusive of an upfront payment and subsequent payments upon achievement of certain regulatory and commercial milestones. 'At SiteOne, we've spent more than a decade advancing a vision to deliver safer, more effective, non-opioid therapies for patients suffering from pain and other sensory hyperexcitability disorders,' said John Mulcahy, Ph.D., chief executive officer and cofounder of SiteOne Therapeutics. 'Lilly shares our deep commitment to scientific rigor, innovation, and patient-centered drug development. We believe their global capabilities and neuroscience leadership will accelerate our efforts to realize the full potential of STC-004 and our broader platform. This acquisition reflects the expertise and dedication of the SiteOne team and marks an exciting new chapter in our mission to transform pain treatment.' The transaction is subject to customary closing conditions. Lilly will determine the accounting treatment of this transaction in accordance with Generally Accepted Accounting Principles (GAAP) upon closing. This transaction will thereafter be reflected in Lilly's financial results and financial guidance. For Lilly, J.P. Morgan Securities LLC is acting as exclusive financial advisor and Jones Day is acting as legal counsel. For SiteOne, Centerview Partners LLC is acting as exclusive financial advisor and Skadden, Arps, Slate, Meagher & Flom LLP and Cooley LLP are acting as legal counsel. About SiteOne Therapeutics SiteOne Therapeutics is a clinical-stage biopharmaceutical company advancing a novel class of highly selective small molecule inhibitors targeting Nav1.7, Nav1.8, and other ion channels to treat pain, cough and other conditions involving hyperexcitability of the peripheral nervous system. Since its inception, SiteOne has been dedicated to the development of safe and effective pain therapeutics without the significant addiction potential and side effects of opioids. The company is also advancing additional novel drug candidates that exhibit precise selectivity for individual ion channel subtypes to treat other sensory hyperexcitability disorders such as chronic cough and chronic ocular surface pain. For more information, visit About Lilly Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit and or follow us on Facebook, Instagram, and LinkedIn. F-LLY Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the benefits of Lilly's acquisition of SiteOne and SiteOne's product candidates for treating pain, and reflects Lilly's current beliefs and expectations. However, as with any such undertaking, there are substantial risks and uncertainties in implementing the acquisition and in the process of drug research, development, and commercialization. Among other things, there can be no guarantee that Lilly will realize the expected benefits of the acquisition, that the acquisition will achieve the results discussed in this release or that the acquisition will yield commercially successful products. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release. View original content to download multimedia: SOURCE Eli Lilly and Company
Yahoo
27-05-2025
- Business
- Yahoo
Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics
Transaction will augment Lilly's efforts to advance non-opioid medicines for pain management INDIANAPOLIS, May 27, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics, Inc. ("SiteOne"), a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, today announced a definitive agreement for Lilly to acquire SiteOne. The transaction includes STC-004, a Phase 2 ready Nav1.8 inhibitor being studied for the treatment of pain. STC-004 may represent a next-generation, non-opioid treatment for patients suffering from chronic pain. "The global burden of chronic pain continues to increase, and an effective non-opioid treatment remains elusive," said Mark Mintun, Lilly group vice president Neuroscience Research and Development. "Lilly is eager to continue the development of STC-004 with the outstanding SiteOne team as part of our efforts to advance novel, addiction-free pain therapies. Innovation in pain management is critical to address the unmet needs of millions of patients around the world." Under the terms of the agreement, Lilly will acquire SiteOne and SiteOne shareholders could receive up to $1.0 billion in cash, inclusive of an upfront payment and subsequent payments upon achievement of certain regulatory and commercial milestones. "At SiteOne, we've spent more than a decade advancing a vision to deliver safer, more effective, non-opioid therapies for patients suffering from pain and other sensory hyperexcitability disorders," said John Mulcahy, Ph.D., chief executive officer and cofounder of SiteOne Therapeutics. "Lilly shares our deep commitment to scientific rigor, innovation, and patient-centered drug development. We believe their global capabilities and neuroscience leadership will accelerate our efforts to realize the full potential of STC-004 and our broader platform. This acquisition reflects the expertise and dedication of the SiteOne team and marks an exciting new chapter in our mission to transform pain treatment." The transaction is subject to customary closing conditions. Lilly will determine the accounting treatment of this transaction in accordance with Generally Accepted Accounting Principles (GAAP) upon closing. This transaction will thereafter be reflected in Lilly's financial results and financial guidance. For Lilly, J.P. Morgan Securities LLC is acting as exclusive financial advisor and Jones Day is acting as legal counsel. For SiteOne, Centerview Partners LLC is acting as exclusive financial advisor and Skadden, Arps, Slate, Meagher & Flom LLP and Cooley LLP are acting as legal counsel. About SiteOne TherapeuticsSiteOne Therapeutics is a clinical-stage biopharmaceutical company advancing a novel class of highly selective small molecule inhibitors targeting Nav1.7, Nav1.8, and other ion channels to treat pain, cough and other conditions involving hyperexcitability of the peripheral nervous system. Since its inception, SiteOne has been dedicated to the development of safe and effective pain therapeutics without the significant addiction potential and side effects of opioids. The company is also advancing additional novel drug candidates that exhibit precise selectivity for individual ion channel subtypes to treat other sensory hyperexcitability disorders such as chronic cough and chronic ocular surface pain. For more information, visit About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit and or follow us on Facebook, Instagram, and LinkedIn. F-LLY Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the benefits of Lilly's acquisition of SiteOne and SiteOne's product candidates for treating pain, and reflects Lilly's current beliefs and expectations. However, as with any such undertaking, there are substantial risks and uncertainties in implementing the acquisition and in the process of drug research, development, and commercialization. Among other things, there can be no guarantee that Lilly will realize the expected benefits of the acquisition, that the acquisition will achieve the results discussed in this release or that the acquisition will yield commercially successful products. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release. Refer to: Ashley Hennessey; gentry_ashley_jo@ 317-416-4363 (Media) Michael Czapar; czapar_michael_c@ 317-617-0983 (Investors) Jessica Yingling; jessica@ 858-344-8091 (SiteOne) View original content to download multimedia: SOURCE Eli Lilly and Company Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
